Kelly Bolton, MD, PhD

Specializes In
  • Cancer (Oncology)
  • Bone Marrow Transplant


Sees Patients For

Genetic predisposition to cancer clonal hematopoiesis

Hospital Affiliations

  • Barnes-Jewish Hospital



Board Certifications

  • Medicine
  • Oncology

Academic Title(s)

Assistant Professor, Medicine
Division of Oncology
Section of Bone Marrow Transplantation & Leukemia

Research Interests

Cancer genetics, epidemiology, genetic susceptibility to cancer, clonal hematopoiesis

Publications & Research

View research profile »


Fellowship: Oncology

2018 Memorial Sloan Kettering Cancer Center, New York, NY

Residency: Medicine

2015 Weill Cornell Medicine-NYP, New York, NY

Medical Degree

2013 UCLA School of Medicine, Los Angeles, CA

PhD: Genetic Epidemiology

2011 University of Cambridge, Cambridge, United Kingdom

Financial Disclosures
  • GoodCell
    • Equity: Yes
    • Reporting Date: 05/01/2023

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.